Update on progress of MPP sublicensees
|
|
- Michael Chandler
- 5 years ago
- Views:
Transcription
1 Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018
2 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed agreements with nine patent holders for 13 HIV antiretrovirals, two hepatitis C direct-acting antivirals, one tuberculosis treatment and one HIV technology platform Licensed products are developed by multiple MPP licensees, with an aim of encouraging competition, reducing market prices and providing faster access to medicines for people living with HIV, hepatitis C (HCV) and tuberculosis (TB) in lowand middle-income countries (LMICs) Generic medicines are developed and filed with stringent regulatory authorities such as the U.S. Food and Drug Administration (USFDA) and the World Health Organization prequalification (WHO-PQ), ensuring availability of quality assured products in LMICs This presentation gives a snapshot of the development of each licensed product and when the product may be filed with regulators. It also shows which countries the local filing is taking place in and when thereby providing a clearer picture of availability of new formulations in each country
3 MPP s partnership with patent holders lopinavir ritonavir atazanavir nevirapine bictegravir cobicistat elvitegravir (separate paediatrics and adults licences) daclatasvir (HCV) (non-assert) emtricitabine tenofovir Alafenamide tenofovir Disoproxil darunavir (paed) (non-assert) sutezolid (TB) raltegravir (paed) darunavir related ravidasvir (HCV) valganciclovir (pricing agreement) solid drug nanoparticles technology for HIV abacavir (paed) dolutegravir (paed) dolutegravir (adults)
4 Snapshot of MPP sublicences AbacavirPaed Paed Abacavir 1 Atazanavir Atazanavir 6 Bictegravir Bictegravir 10 Cobicistat Cobicistat 8 Daclatasvir Daclatasvir 10 Dolutegravir Dolutegravir 19 * Elvitegravir Elvitegravir Lopinavir/ Ritonavir Paed Lopinavir/ Ritonavir Adult Raltegravir Paed 2 Tenofovir Alafanamide Tenofovir Disoproxil Total sublicences with 23 manufacturers; 160 active projects *MOU executed
5 Triangle Charts: A Snapshot Triangle charts represent a comparative analysis of each MPP licensee on filings with USFDA and WHO-PQ for each product See following slides for explanation
6 Filing of generics with WHO-PQ and/or USFDA Triangle charts explained (1/5)
7 Triangle charts explained (2/5) No. of companies that received approval out of total companies filed with WHO/stringent regulatory authorities (SRA)
8 Triangle charts explained (3/5) Outlined triangles (s) represent licensees planning to file Each coloured triangle corresponds to a different licensee
9 Triangle charts explained (4/5) Triangle charts represent a comparative analysis of each MPP licensee on filings with USFDA and WHO-PQ for each product Filled triangles (q) represent licensees who have filed
10 Triangle charts explained (5/5) Triangle charts represent a comparative analysis of each MPP licensee on filings with USFDA and WHO-PQ for each product A circled triangle represents a licensee who has received approval
11 Dolutegravir
12 DTG 50mg The above chart shows nine MPP licensees are developing DTG 50mg, of which: Ø Six companies have filed with WHO-PQ; of which Cipla and Hetero have received approval Ø Seven companies have filed with USFDA; of which Aurobindo, Cipla and Mylan have received approvals Emcure and Hetero have received Expert Review Panel (ERP) approvals In total, five companies are ready to supply DTG 50mg
13 DTG 50mg: Country-wise Filing Status Botswana Côte d'ivoire India Kenya Nicaragua Myanmar Tanzania Ukraine Uzbekistan Approved (9) 22.1% PLHIV Filed (24) 66.4% PLHIV in LMICs Burundi Kyrgyztan Senegal Congo Malawi Sierra Leone DR Congo Mauritius South Africa El Salvador Mozambique Sudan Ethiopia Namibia Uganda Gabon Nigeria Vietnam Ghana Pakistan Zambia Guyana Rwanda Zimbabwe Generic DTG has been filed in 33 countries, of which approval is received from nine. Another 30 filings are planned for 2018 (covering an additional 11.5% of people living with HIV (PLHIVs) in LMICs)
14 DTG 50mg Dispersible Tablets Four MPP licensees are developing DTG dispersible formulation, of which: Ø Two plan to file with WHO-PQ in Q3-19 Ø One plans to file with USFDA in early 2019 and another three by second half of 2019
15 TDF/3TC/DTG (TENOFOVIR DISOPROXIL/LAMIVUDINE/DOLUTEGRAVIR) 14 MPP licensees are currently developing TDF/3TC/DTG, of which: Ø Seven have filed with WHO-PQ Ø Seven have filed with USFDA; of which Aurobindo, Hetero and Mylan have received approvals Cipla, Hetero, Macleods, and Sun have received ERP approval In all, three generic versions of TLD are already in the market and an additional three are expected to be launched soon
16 TDF/3TC/DTG: country-wise filing status Approved (6) (19.4% PLHIV in LMICs) Botswana Côte d'ivoire India Kenya Malawi Uzbekistan Filed (25) (69.2% PLHIV in LMICs) Benin Ghana South Africa Burkina Faso Madagascar Tanzania Burundi Mali Uganda Cameroon Mozambique Ukraine Congo Namibia Vietnam DR Congo Niger Zambia El Salvador Nigeria Zimbabwe Ethiopia Rwanda Gabon Senegal Generic TLD has been filed in 31 countries, of which approval is received from six Another 25 filings are planned for 2018 (covering an additional 7.7% PLHIVs in LMICs)
17 TAF/FTC/DTG (TENOFOVIR ALAFENAMIDE/EMTRICITABINE/DOLUTEGRAVIR) Due to lack of clinical data, TAF is not on the WHO Guidelines as of now. However, generics have already started developing TAF combinations 10 MPP licensees are developing TAF/FTC/DTG, of which: Ø Mylan has filed with USFDA and received approval Ø Two additional filings are planned by end of 2018 We anticipate development by additional licensees to accelerate once there is an update on WHO s position about use of TAF-containing formulations
18 Other formulations
19 TAF/FTC (TENOFOVIR ALAFENAMIDE/EMTRICITABINE) Five MPP licensees are developing TAF/FTC, of which: Ø One company has filed with USFDA Ø One company is planning to file with USFDA in Q4-18 Ø An additional three companies are expected to file in 2019 We anticipate additional licensees to start development once greater clarity is obtained through WHO on the use of TAF and its combinations Note: Gilead has direct licences with additional manufacturers, details of which are not captured here
20 ATV/R (ATAZANAVIR/RITONAVIR) Six MPP licensees are working on ATV/r formulation, of which: Ø Mylan and Emcure received SRA approvals and have already commercialised the product Ø Cipla has received WHO-PQ approval in 2017; is yet to commercialise Ø Additionally three companies are planning to file the product Currently approved in 28 countries and filed in another 15 countries Total filing coverage: 88.7% of PLHIV in LMICs
21 LPV/r Seven companies are working on the LPV/r formulation, of which: Two MPP licensees approved: Aurobindo and Hetero Three additional companies (non-licensees) approved: Cipla, Macleods, Mylan And additional two companies are planning to file in the next one year Currently approved in 39 countries and filed in another 39 countries Total filing coverage: 85.1% of PLHIV in LMICs
22 Paediatric HIV
23 Paediatric projects 1 LPV/r (sprinkles in sachet or minitabs in capsule) Three companies working on this product: Ø Cipla has received USFDA approval Ø Another has filed with WHO-PQ and USFDA in Q1-18 Ø The third plans to file with USFDA and WHO-PQ in Q3-19 LPV/r/ABC/3TC (sprinkles in sachet or minitabs in capsule) Three companies working on this product: Ø One plans to file with USFDA and WHO-PQ in Dec-18 Ø Another plans to file with USFDA and WHO-PQ in 2019 Ø Another developing, filing status and plans unknown ABC/3TC/EFV Three companies working on the product Ø Filing plans in 2019 ABC/3TC/DTG Multiple companies interested in development, awaiting WHO recommendation on dosage
24 Daclatasvir
25 DAC 30mg and 60mg Seven MPP licensees currently developing the two products, of which: Ø Four have filed with WHO-PQ Ø Three filings planned in 2019 Cipla, Hetero and Mylan have received ERP approvals Currently approved in 16 countries and filed in another 30 countries
26 DAC 30mg & 60MG: COUNTRY-WISE FILING STATUS Approved (16) Cambodia Indonesia Chad Malawi Congo Mongolia DR Congo Myanmar Ethiopia Nicaragua Gabon Pakistan Guyana Turkmenistan India Uzbekistan Filed (30) Azerbaijan Ghana Rwanda Benin Guatemala Senegal Bolivia Haiti Sri Lanka Botswana Kenya Sudan Burkina Faso Lao PDR Suriname Burundi Namibia Tanzania Cameroon Nepal Uganda Côte d'ivoire Nigeria Vietnam Dominican Republic Paraguay Zambia Generic DAC has been filed in 46 countries, of which approval is received from 16
27 DAC/SOF Currently four MPP licensees are developing DAC/SOF combination, of which: Ø First filing with WHO-PQ is expected in Q3-18 Ø Another three companies plan to file in the next year Currently approved in three countries and filed in another 14 countries
28 DAC/SOF: Country-wise filing status and plan Approved (3) Filed (14) India Libya Uganda Dominican Republic Ghana Ethiopia Kenya Namibia Guyana Nigeria Paraguay Suriname Vietnam Zambia Myanmar Nicaragua Zimbabwe DAC/SOF has been filed in 17 countries, of which approval is received from three
29 MPP s Impact The MPP, through licensing agreements has enabled developing countries to benefit from access to affordable, quality-assured generics. Our impact is measured by calculating savings from the purchase of medicines developed by our licensees in additional countries where such generics sale was earlier not possible. Direct savings generated by the MPP are estimated to be USD 2.3 billion (net present value) by 2028, representing an estimated cost-benefit ratio of 1:43, which means for every USD 1 spent on MPP, the global public health community saves USD 43. The saving of USD 2.3 billion is equivalent to more than 24 million PLHIV receiving first-line ART in LMICs for one year at average prices today.
30 Impact of MPP agreements till DEC 2017 (HIV, HCV products) 128 countries MPP licensees distributing generics $553mn Savings 17mn patient-years Serviced by MPP licensees 146 new instances of countries Benefitted from generic competition through MPP agreements 89% average drop In formulation prices after MPP agreements Review and independent assurance of impact by KPMG* USD mn Cumulative savings and patients serviced through MPP licensees Patient years (mn) Savings Patient Years * Available at:
31 Projected Impact of MPP Agreements Till 2028 (HIV products) The economic model projects the MPP will generate $6.8 billion in direct savings by 2028 $6.8 billion Total Direct Savings for Net Impacted PLHIVs in Expanded Territories $447 million* Total Direct Savings for Net Impacted PLHIVs in Expanded Territories till Dec-2017 * Calculation of actual impact (from data received by sub-licensees) 1:130 Cost-Benefit Ratio of MPP Operating Budget to Direct Savings
32 Thank you
THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy
THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy LEARNING FROM THE HIV RESPONSE EVOLUTION OF AIDS DRUG PRICES: 2000-2008 Source: MSF (2008)
More informationEligibility List 2018
The Global Fund s 2017-2022 strategy and allocation-based approach enables strategic investment to accelerate the end of HIV/AIDS, tuberculosis and malaria and build resilient and sustainable systems for
More informationCurrent State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2
Current State of Global HIV Care Continua Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2 1) International Association of Providers of AIDS Care
More informationAnnex 2 A. Regional profile: West Africa
Annex 2 A. Regional profile: West Africa 355 million people at risk for malaria in 215 297 million at high risk A. Parasite prevalence, 215 Funding for malaria increased from US$ 233 million to US$ 262
More informationPneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division Update: October 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Outlook October 2013 Update Key updates
More informationWhat is Treatment Optimisation (TO)
Outline What is treatmen optimisation Why is treatment optimisation important for the future of HIV treatment and care Drugs optimisation Some strategies for moving the TO agend forward Discussion: Why
More informationUpdate on Progress of MPP Sub-licensees July 2017
HOW THE MPP WORKS? Update on Progress of MPP Sub-licensees July 2017 In-Licensing: Concluded Agreements Lopinavir Ritonavir (separate paediatrics and adults licences) Atazanavir Daclatasvir (HCV) Nevirapine
More informationEXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT
UNICEF / Zar Mon Annexes EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT This report includes nine nutrition statistics, as per the 2017 Global Nutrition Report. These
More informationFunding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia
Funding for AIDS: The World Bank s Role Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia Outline New resources needs estimates Bridging the gap Global overview of
More informationComparative Analyses of Adolescent Nutrition Indicators
Comparative Analyses of Adolescent Nutrition Indicators Rukundo K. Benedict, PhD The DHS Program Stakeholders Consultation on Adolescent Girls Nutrition: Evidence, Guidance, and Gaps October 30 31, 2017
More informationImpact Dashboard - August 2014
Impact Dashboard - By, PSI and its network members averted an estimated 29.7 million DALYs globally. PSI has met 53.3% of the strategic plan (SP) target to avert 198.7 million DALYs, and 53.0% of the SP
More informationTHE CARE WE PROMISE FACTS AND FIGURES 2017
THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148
More informationImpact Dashboard - October 2014
Impact Dashboard - 2014 By 2014, PSI and its network members averted an estimated 44.2 million DALYs globally. PSI has met 60.6% of the strategic plan (SP) target to avert 198.7 million DALYs, and 56.4%
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved UNAIDS / JC2225E The designations employed and the presentation of the material in this publication
More informationGlobal Fund Mid-2013 Results
Global Fund Mid-2013 Results This fact sheet outlines some of the common questions and answers regarding results reported by Global Fund-supported programs, including the principles and approach in determining
More informationMalaria Funding. Richard W. Steketee MACEPA, PATH. April World Malaria Day 2010, Seattle WA
Malaria Funding Richard W. Steketee MACEPA, PATH April World Malaria Day 2010, Seattle WA Malaria Funding Is there a plan? Is there money? Where does the money come from? Is the money moving efficiently?
More informationINTRODUCTION TO THE MEDICINES PATENT POOL
www.medspal.org TABLE OF CONTENTS 1. Introduction to the Medicines Patent Pool 2. Background on MedsPaL 3. What patent information is included in MedsPaL? 4. What licensing and data exclusivity information
More informationGlobal Fund ARV Fact Sheet 1 st June, 2009
Global Fund ARV Fact Sheet 1 st June, 2009 This fact sheet outlines the principles and approach in determining the number of people on antiretroviral drugs (ARVs) for HIV/AIDS treatment, with a breakdown
More informationScaling Up Antiretroviral Treatment Sustainably
Scaling Up Antiretroviral Treatment Sustainably Gilead Sciences Programs in Developing Countries For more than a decade, Gilead Sciences has been a leader in the development of antiretroviral therapy for
More informationBCG. and your baby. Immunisation. Protecting babies against TB. the safest way to protect your child
BCG and your baby Protecting babies against TB Immunisation the safest way to protect your child This leaflet is about the BCG (Bacillus Calmette-Guerin) vaccination that is being offered to protect your
More informationimpact dashboard year-end with 2017 coefficients
impact dashboard - 2017 year-end with 2017 coefficients In 2017, PSI averted an estimated 30.5 million DALYs and provided 20 million CYPs globally. PSI met global 2017 program targets for DALYs averted
More informationChallenges and Opportunities to Optimizing the HIV Care Continuum Can We Test and Treat Enough People to Make a Seismic Difference by 2030?
Challenges and Opportunities to Optimizing the HIV Care Continuum Can We Test and Treat Enough People to Make a Seismic Difference by 2030? Reuben Granich, MD, MPH Strategic and Scientific Advisor International
More informationGlobal Fund Results Fact Sheet Mid-2011
Global Fund Results Fact Sheet Mid-2011 This fact sheet outlines some of the common questions and answers regarding results reported by Global Fund-supported programs, including the principles and approach
More informationAIDS in Africa. An Update. Basil Reekie
AIDS in Africa An Update Basil Reekie Contents General Statistics The trend of HIV in Africa Ugandan experience UNAIDS 2006 Latest African Statistics by Country HIV Intervention Light at the end of the
More informationמדינת ישראל. Tourist Visa Table
Updated 23/05/2017 מדינת ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. Exe = exempted Req = required Press the first
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationRotavirus Vaccine: Supply & Demand Update. UNICEF Supply Division
Rotavirus Vaccine: & Demand Update UNICEF Division July 0 Rotavirus Vaccine (RV): & Demand Update July This update provides new information on countries and their scheduled RV introductions, forecasted
More informationOutcomes of the Global Consultation Interim diagnostic algorithms and Operational considerations
Outcomes of the Global Consultation Interim diagnostic algorithms and Operational considerations Briefing on Xpert MTB/RIF. Geneva, 21 February, 2011 Fuad Mirzayev TB Laboratory Strengthening and Diagnostics
More informationמדינת ישראל. Tourist Visa Table. Tourist visa exemption is applied to national and official passports only, and not to other travel documents.
Updated 25/05/2015 ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. (C) Bearers of official passports requiring tourist
More informationJOINT TB AND HIV PROGRAMMING
JOINT TB AND HIV PROGRAMMING Haileyesus Getahun, WHO. On behalf of the Global Fund Interagency TB and HIV Working Group (Global Fund, PEPFAR, Stop TB Partnership, UNAIDS, WHO) I was admitted in a hospital
More informationScaling Up Antiretroviral Treatment Sustainably
Scaling Up Antiretroviral Treatment Sustainably Gilead Sciences Programs in Developing Countries For more than a decade, Gilead Sciences has been a leader in the development of antiretroviral therapy for
More informationOptimizing Paediatric and Adolescent ART: Challenges and Opportunities
Optimizing Paediatric and Adolescent ART: Challenges and Opportunities Dr Nandita Sugandhi ICAP at Columbia University PATA 2017 Continental Summit 24 October, 2017 Johannesburg South Africa Overview What
More informationCOLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)
COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) Sushila Maharjan Senior Manager, Innovative Finance International Conference on Sustainable Cooling World Bank Washington DC - 29 November 2018 Reach
More information1. Consent for Treatment This form must be completed in order to receive healthcare services in the campus clinic.
HEALTH & WELLNESS SERVICES INSTRUCTIONS FOR COMPLETING THE REQUIRED MEDICAL FORMS FOR: U.S. CITIZENS 18 YEARS OF AGE OR OLDER AT THE TIME THE FORMS ARE COMPLETED. THIS REQUIREMENT MUST BE COMPLETED WHETHER:
More information#1 #2 OR Immunity verified by immune titer (please attach report) * No titer needed if proof of two doses of Varicella provided
Student Information: Date of Birth: There are two ways to provide us with your immunization information. 1) Students can have their healthcare provider fill out and sign the form below. A healthcare provider
More informationAPPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS
WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2011 APPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS (SEE TABLE 4.9) Africa The Americas South-East Asia Europe Eastern Mediterranean Western Pacific
More informationUpdate from GAVI Aurelia Nguyen
Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,
More informationimpact dashboard - august 2018
impact dashboard - august 2018 PSI 2015 As of August, PSI averted an estimated 15.2 M DALYs, provided 10.9 M CYPs, and reached 16.7 M users globally. Globally PSI has reached at least 16.7 million users
More informationFebruary Health Impact Report 2010
February Health Impact Report 1,391,742 Feb'10 DALYs: 7.5% of strategic target goal is 14% 26% decrease from Feb'09 Feb' 10 DALYs include: :: 1,350,675 product s :: 41,067 BCC DALYs todate in 9 countries:
More informationImpact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries
August 29, 2018 Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries Thirteenth International Rotavirus Symposium 29 31 August 2018 Minsk, Belarus Frédéric Debellut Health Economist,
More informationWhat is this document and who is it for?
Measles and Rubella Initiative s Standard Operating Procedures for Accessing Support for Measles and Rubella Supplementary Immunization Activities During 2016 In the context of measles and rubella elimination
More informationSGCEP SCIE 1121 Environmental Science Spring 2012 Section Steve Thompson:
SGCEP SCIE 1121 Environmental Science Spring 2012 Section 20531 Steve Thompson: steventhompson@sgc.edu http://www.bioinfo4u.net/ 1 First, a brief diversion... Into... how to do better on the next exam,
More informationimpact dashboard - june 2018
impact dashboard - june 2018 As of June, PSI averted an estimated 11.3 M DALYs, provided 8.1 M CYPs, and reached 12.5 M users globally. Ethiopia, Zambia, and Cameroon have made considerable progress on
More informationANNEX 3: Country progress indicators
: progress indicators 541 : COUNTRY PROGRESS INDICATORS 2006 REPORT ON THE GLOBAL AIDS EPIDEMIC Annex 3 : COUNTRY PROGRESS INDICATORS As of March 2006, 115 countries had reported indicators on progress
More informationOctober 2011 Monthly Health Impact Report
HEALTH IMPACT REPORT October Monthly Health Impact Report OCTOBER, PSI AVERTED AN ESTIMATED 17,899,945 DALYs (88% of the strategic target, the goal is 80%). This is a 66% increase from. Oct. 11 DALYs averted
More informationimpact dashboard - september 2018
impact dashboard - september 2018 PSI 2015 As of, PSI averted an estimated 17.1 M DALYs, provided 12.5 M CYPs, and reached 18.4 M users globally. Globally PSI has reached at least 18.4 million users across
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationCertificate of Immunization
Certificate of Immunization Required of all students (Page 1 of 5) QUESTIONS? 440-775-8180 or student.health@oberlin.edu (e-mail preferred) RETURN TO: Oberlin College Student Health Services 247 W. Lorain
More informationTT Procured by UNICEF
TT TT Procured by UNICEF 2001-08 250,000,000 200,000,000 150,000,000 100,000,000 50,000,000 0 2001 2002 2003 2004 2005 2006 2007 2008 Routine SIA TT historical demand and forecast overview Upcoming Tender
More informationThe Global HIV/AIDS Epidemic, risk factors for transmission. and Global response. Training Course in Sexual and Reproductive Health Research 2014
The Global HIV/AIDS Epidemic, risk factors for transmission and Global response Training Course in Sexual and Reproductive Health Research 2014 Txema Calleja HIV Dept. July 2014 Data based in UNAIDS and
More informationimpact dashboard - may 2018
impact dashboard - may 2018 As of May, PSI averted an estimated 8.0 M DALYs, provided 6.2 M CYPs, and reached 8.1 M users globally. In May alone, PSI added 2.6 M users toward the goal of 90 M reached by
More informationTipping the dependency
BREAKING NEWS Meeting the investment challenge Tipping the dependency balance Domestic investments exceed international investments total reaching US$ 8.6 billion. 40 countries fund more than 70% of their
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2016 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2017 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2016 Highlights 2016
More informationIX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR. Eduard Bos The World Bank
IX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR Eduard Bos The World Bank A. INTRODUCTION This paper discusses the relevance of the ICPD Programme of Action for the attainment of
More informationWorld Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts
World Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts (charts in colour) (These charts will be updated in 2014) 2 1. Introduction 2. Instructions on how to use
More informationMalnutrition prevalences by country and year, from survey data and interpolated for reference years (1990, 1995, 2000)
Recent trends in malnutrition in developing regions 109 Annex 1 Malnutrition prevalences by country and year, from survey data and interpolated for reference years (1990, 1995, ) The tables in this Annex
More informationVarious interventions for controlling sexually transmitted infections have proven effective, including the syndromic
levels, as understaffing is a chronic issue in all the countries that are scaling up male circumcision. Current achievements notwithstanding, it is necessary to reinforce and strengthen national political
More informationThis portion to be completed by the student Return by July 1 Please use ballpoint pen
This portion to be completed by the student Return by July 1 Please use ballpoint pen Start term: Fall Exploration Spring Summer Year: Class year: Freshman Sophomore Junior Senior Transfer Full name: Preferred:
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2016 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2017 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2016 Highlights 2016
More informationForecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta
Forecasting pipeline ARVs Joseph Perriëns Sandeep Juneja Aastha Gupta Presently: lack of visibility causes a gap between demand and generic production for new drugs Patent Holder R&D Marketing 3-4 yrs
More informationFinancing malaria control
Chapter 6. Financing malaria control The three major sources of funds for malaria control pro - grammes are national government spending, external assistance from donors and household or private out-of-pocket
More informationCONTRACEPTIVE SOCIAL MARKETING STATISTICS
2017 CONTRACEPTIVE SOCIAL MARKETING STATISTICS September 2018 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington DC 20006 SOCIAL MARKETING STATISTICS 2017 Highlights 2017
More informationSeizures of ATS (excluding ecstasy ), 2010
Seizures of ATS (excluding ecstasy ), 2010 (countries and territories reporting seizures* of more than 10 kg) 9 5.1 8.7 12.9 Ghana Armenia 0.7 9.9 1 2.1 Syrian Arab Republic Korea (Republic of) Iraq Islamic
More informationFORMS MUST BE COMPLETED PRIOR TO THE START OF YOUR FIRST SEMESTER
HEALTH & WELLNESS SERVICES INSTRUCTIONS FOR COMPLETING THE REQUIRED MEDICAL FORMS FOR: U.S. CITIZENS WHO ARE NOT 18 YEARS OF AGE AT THE TIME THE FORMS ARE COMPLETED. THIS REQUIREMENT MUST BE COMPLETED
More informationMaternal Deaths Disproportionately High in Developing Countries
EMBARGOED until Monday, 20 October, 6am GMT HQ/2003/24 20 October 2003 CF/DOC/PR/2003-82 Maternal Deaths Disproportionately High in Developing Countries African women are 175 times more likely to die in
More informationUNDERGRADUATE STUDENT HEALTH PACKET
UNDERGRADUATE STUDENT HEALTH PACKET Deadlines: Fall: July 15 th Spring: December 1st Enclosed Forms/Documents: Type of Students Required For: Comments: Undergraduate Vaccine Form Physical Examination Form
More informationFoot-and-Mouth Disease Situation Food and Agriculture Organization of the United Nations Monthly Report
Foot-and-Mouth Disease Situation Food and Agriculture Organization of the United Nations Monthly Report October 2013 I N F O R M A T I O N S O U R C E S U S E D: Databases: OIE WAHID World Animal Health
More informationPROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA
5 July 2011 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-first session Yamoussoukro, Côte d Ivoire, 29 August 2 September 2011 Provisional agenda item 17.1 PROGRESS REPORT ON THE ROAD MAP FOR
More informationGlobal malaria mortality between 1980 and 2010: a systematic analysis
Global malaria mortality between 1980 and 2010: a systematic analysis Christopher J L Murray, Lisa C Rosenfeld, Stephen S Lim, Kathryn G Andrews, Kyle J Foreman, Diana Haring, Nancy Fullman, Mohsen Naghavi,
More information2002 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2002 CONTRACEPTIVE SOCIAL MARKETING STATISTICS Courtesy of DKT International 1120 19th Street, NW Suite 610 July 2003 Washington, DC 20036 1 SOCIAL MARKETING STATISTICS 2001 Highlights 2002 2001 2000 CYPs
More information2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2007 Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 www.dktinternational.org 1 SOCIAL MARKETING STATISTICS 2006 Highlights
More informationWhy Invest in Nutrition?
Why Invest in Nutrition? Meera Shekar Human Development Network World Bank 2006 Three key Issues Why reducing malnutrition is essential to poverty reduction? Is malnutrition a BIG problem? How can we improve
More informationAboubacar Kampo Chief of Health UNICEF Nigeria
Aboubacar Kampo Chief of Health UNICEF Nigeria Many thanks to UNICEF colleagues in Supply Division-Copenhagen and NY for contributing to this presentation Thirty-five countries are responsible for 98%
More informationAGaRT The Advisory Group on increasing access to Radiotherapy Technology in low and middle income countries
AGaRT The Advisory Group on increasing access to Radiotherapy Technology in low and middle income countries Together against Cancer The Advisory Group on Increasing Access to Radiotherapy To address the
More informationClosing the loop: translating evidence into enhanced strategies to reduce maternal mortality
Closing the loop: translating evidence into enhanced strategies to reduce maternal mortality Washington DC March 12th 2008 Professor Wendy J Graham Opinion-based decisionmaking Evidence-based decision-making
More informationFinancing the HIV response in sub- Saharan Africa from domestic sources: moving beyond a normative approach
Financing the HIV response in sub- Saharan Africa from domestic sources: moving beyond a normative approach Michelle Remme 1, Mariana Siapka 1, Olivier Sterck 2, Mthuli Ncube 2, Charlotte Watts 1 & Anna
More informationHIV and development challenges for Africa Catherine Hankins, Associate Director & Chief Scientific Adviser to UNAIDS
Catherine, Associate Director & Chief Scientific Adviser to Session: Challenges of globalisation, regional integration and development of Africa 10 th Anniversary of the Centre for the Study of Globalisation
More informationPresentation by Dr Philippe Douste-Blazy. Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development
Presentation by Dr Philippe Douste-Blazy Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development The Millennium Goals : Hope for Humanity 2000 UN Millennium Summit
More informationScaling Up Nutrition Action for Africa
Scaling Up Nutrition Action for Africa Where are we and what challenges are need to be addressed to accelerate malnutrition? Lawrence Haddad Global Alliance for Improved Nutrition Why should African political
More information25 October 2005 INTRODUCTION
Relative market share of different antiretroviral compounds in low and middle income countries in 2004 and 2005: an analysis of 2 public domain data bases Prepared by the AIDS Medicines and Diagnostics
More informationADMINISTRATIVE AND FINANCIAL MATTERS. Note by the Executive Secretary * CONTENTS. Explanatory notes Tables. 1. Core budget
UNITED NATIONS Distr. GENERAL 13 October 1997 ENGLISH ONLY SUBSIDIARY BODY FOR IMPLEMENTATION Seventh session Bonn, 20-29 October 1997 Item 9 of the provisional agenda ADMINISTRATIVE AND FINANCIAL MATTERS
More informationThe Immunization Record is available to download from the Health Insurance and Immunizations website at drexel.edu/hii/forms.
IMMUNIZATIONS The Immunization Record is available to download from the Health Insurance and Immunizations website at drexel.edu/hii/forms. To ensure the safety of all students, Drexel requires all full-time
More informationAfrica s slow fertility transition
Africa s slow fertility transition John Bongaarts Population Council, New York Süssmilch Lecture Max Planck Institute, Rostock 3 Sep 215 Billions 4 3 Population projections for sub-saharan Africa 215 projection
More informationHPV Vaccine Lessons Learned & New Ways Forward
HPV Vaccine Lessons Learned & New Ways Forward The Gavi Alliance June 2016, Geneva www.gavi.org Overview 1 Background 2 Lessons learned 3 New Way Forward 2 1 Background 3 HPV Background HPV is responsible
More informationMATERNAL, NEWBORN, AND CHILD HEALTH
MATERNAL, NEWBORN, AND CHILD HEALTH SESSION OBJECTIVES Introduction to GHSC-PSM Maternal, Newborn, and Child Health (MNCH) strategy and priorities Defining MNCH commodities Overview of historical and current
More informationHealth Services Immunization and Health Information
Your complete record for required vaccines (Part II) must be on file in our Health Center before the start of classes or you will be MEDICALLY WITHDRAWN FROM CLASSES per NYS Public Health Laws 2165 and
More informationUpdate on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012
PMTCT Update Update on PMTCT Margarett Davis, MD, MPH Chief, Maternal and Child Health Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention (CDC) African Health Profession Regulatory
More informationEpidemiology and economics: modelling the scenarios for the end of AIDS
Epidemiology and economics: modelling the scenarios for the end of AIDS Controlling the HIV Epidemic with Antiretrovirals: from consensus to implementations London, England September 22, 2013 Reuben Granich,
More informationVIEW-hub Report: Global Vaccine Introduction and Implementation
A report on current global access to new childhood vaccines VIEW-hub Report: Global Vaccine Introduction and Implementation December 2016 INTERNAL VERSION Developed from data in VIEW-hub www.view-hub.org
More informationSTUDENT HEALTH SERVICES NEW STUDENT QUESTIONNAIRE
STUDENT HEALTH SERVICES NEW STUDENT QUESTIONNAIRE UC Hastings Student Health Services (SHS) is committed to providing you the best possible medical care, so we need to know about your medical history and
More informationSpectrum. Quick Start Tutorial
Spectrum Quick Start Tutorial March 2005 Table of Contents Introduction... 2 What you will learn... 4 Basic Steps in Using Spectrum... 4 Step 1. Installing Spectrum... 4 Step 2. Changing the language in
More informationDear New Student and Family,
Dear New Student and Family, Enclosed is information regarding the health documents that students must (1) take to their health care provider and (2) upload prior to arriving at Moravian College. Everything
More information2007 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2007 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2008 Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 www.dktinternational.org 1 SOCIAL MARKETING STATISTICS 2007 Highlights
More informationFamily Planning: Succeeding in Meeting Needs To Make a Better World. Amy Tsui April 12, 2011
Family Planning: Succeeding in Meeting Needs To Make a Better World Amy Tsui April 12, 2011 Family Planning, One of the Ten Best Public Health Achievements of the 20 th Century and Now Remarkable health
More informationUNITAID is hosted and administered by the World Health Organization
UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 unitaid@who.int www.unitaid.eu Medicines Patent Pool Chemin Louis-Dunant
More informationPatents and licences on antiretrovirals: A snapshot
2014 Patents and licences on antiretrovirals: A snapshot APRIL 2014 UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland T +41 22 791 55 03 F +41 22 791 48 90 unitaid@who.int
More information2015 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2015 CONTRACEPTIVE SOCIAL MARKETING STATISTICS November 2016 CONNECT WITH US Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 1 SOCIAL MARKETING STATISTICS 2015 Highlights
More information